ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders

ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.Submission of Matters to a Vote of Security Holders.

AbbVie Inc. (AbbVie) held its Annual Meeting of Stockholders on
May5, 2017. The following is a summary of the matters voted on at
that meeting.

(1) The stockholders elected AbbVies ClassII Directors with terms
expiring in 2020, as follows:

Name		For		Against		BrokerNon-Votes
Robert J. Alpern		1,118,328,511		10,737,541		280,277,501
Edward M. Liddy		1,113,185,998		15,880,054		280,277,501
Melody B. Meyer		1,121,539,612		7,526,440		280,277,501
Frederick H. Waddell		1,119,615,307		9,450,745		280,277,501

(2) The stockholders ratified the appointment of Ernst Young LLP
as AbbVies independent registered public accounting firm for
2017, as follows:

For		Against		Abstain
1,392,413,822		14,065,091		2,864,640

(3) The stockholders approved, on an advisory basis, the
compensation of AbbVies named executive officers listed in the
proxy statement for the 2017 annual meeting, as follows:

For		Against		Abstain		BrokerNon-Votes
1,066,989,000		50,885,097		11,191,955		280,277,501

(4) The stockholders did not approve the management proposal
regarding amendment of the certificate of incorporation for the
annual election of directors, as follows:

For		Against		Abstain		BrokerNon-Votes
1,116,988,345		7,082,900		4,994,807		280,277,501

(5) The stockholders did not approve a stockholder proposal to
issue a lobbying report, as follows:

For		Against		Abstain		BrokerNon-Votes
280,902,158		774,007,636		74,156,258		280,277,501

(6) The stockholders did not approve a stockholder proposal to
separate chair and CEO, as follows:

For		Against		Abstain		BrokerNon-Votes
386,900,232		735,332,171		6,833,649		280,277,501

About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products. ABBVIE INC. (NYSE:ABBV) Recent Trading Information
ABBVIE INC. (NYSE:ABBV) closed its last trading session down -0.04 at 66.17 with 4,497,397 shares trading hands.